ZOSUQUIDAR TRIHYDROCHLORIDE IN NEWLY DIAGNOSED AML

ZOSUQUIDAR 三盐酸盐在新诊断的 AML 中的应用

• 批准号: 7375497
• 负责人: Mark Juckett
• 金额: $ 0.34万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375497
• 关键词: ZOSUQUIDAR; TRIHYDROCHLORIDE; NEWLY; DIAGNOSED; AML

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed. (from www.cancer.gov website) Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar trihydrochloride in treating acute myeloid leukemia or anemia. This randomized phase III trial is studying how well giving zosuquidar trihydrochloride together with daunorubicin and cytarabine works compared to daunorubicin and cytarabine alone in treating older patients with newly diagnosed acute myeloid leukemia or anemia that has not responded to previous treatment.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。这项研究已结束。 （来自 www.cancer.gov 网站）化疗中使用的药物使用不同的方法来阻止癌细胞分裂，使其停止生长或死亡。 Zosuquidar triHClate 可以使癌细胞对药物更加敏感，从而帮助柔红霉素和阿糖胞苷杀死更多的癌细胞。目前尚不清楚柔红霉素和阿糖胞苷联合或不联合三盐酸zosuquidar治疗急性髓系白血病或贫血是否更有效。 这项随机 III 期试验正在研究与单独使用柔红霉素和阿糖胞苷相比，将 zosuquidar triHClide 与柔红霉素和阿糖胞苷一起治疗新诊断的急性髓系白血病或对先前治疗无反应的贫血的老年患者的疗效如何。